These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36841031)

  • 21. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
    Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
    Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?
    Harriss LJA; Stevens L; Rayner CJ; Simpson G; Annels NE; Frampton AE
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):223-226. PubMed ID: 38818792
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment.
    Zhang W; Zhang J; Zhang J; Chu J; Zhang Z
    J Nanobiotechnology; 2024 Oct; 22(1):638. PubMed ID: 39420389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
    Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
    Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
    Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
    Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
    Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
    Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
    Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
    [No Abstract]   [Full Text] [Related]  

  • 31. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
    Najafi S; Majidpoor J; Mortezaee K
    Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
    Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
    J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
    Zhang Q; Yang C; Gao X; Dong J; Zhong C
    Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival.
    Wang H; Khattar V; Hensel JA; Ashton R; Lu Y; Sorace AG; Wang Y; Deshane JS; Mieher JL; Deivanayagam C; Ponnazhagan S
    Mol Cancer Ther; 2022 Nov; 21(11):1710-1721. PubMed ID: 36031328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
    Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY
    Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.